Table 1.
Distribution of clinicopathological variables in the SweBCG91RT cohort depending on PDGFRb score
| Variables | PDGFRb-low | PDGFRb-medium | PDGFRb-high | p value* |
|---|---|---|---|---|
| Age (years) | ||||
| ≤ 55 | 82 (26.9%) | 117 (37.4%) | 175 (47.2%) | |
| 55 | 223 (73.1%) | 196 (62.6%) | 196 (52.8%) | < 0.001 |
| Tumor size (mm) | ||||
| ≤ 10 | 94 (35.3%) | 63 (24.7%) | 83 (25.8%) | |
| 11–15 | 105 (39.5%) | 105 (41.2%) | 146 (45.3%) | |
| 16–20 | 42 (15.8%) | 62 (24.3%) | 58 (18%) | |
| > 20 | 25 (9.4%) | 25 (9.8%) | 35 (10.9%) | 0.037 |
| Histological grade | ||||
| I | 48 (16.5%) | 42 (14%) | 56 (15.7%) | |
| II | 182 (62.5%) | 189 (62.8%) | 197 (55.3%) | |
| III | 61 (21%) | 70 (23.3%) | 103 (28.9%) | 0.13 |
| Subtype | ||||
| Luminal A | 192 (66.4%) | 178 (58.6%) | 180 (50.1%) | |
| Luminal B | 67 (23.2%) | 81 (26.6%) | 110 (30.6%) | |
| HER2+ | 14 (4.8%) | 20 (6.6%) | 30 (8.4%) | |
| Triple negative | 16 (5.5%) | 25 (8.2%) | 39 (10.9%) | 0.004 |
| ER status | ||||
| Negative | 46 (15.1%) | 54 (17.3%) | 81 (21.8%) | |
| Positive | 259 (84.9%) | 259 (82.7%) | 290 (78.2%) | 0.066 |
| Endocrine therapy | ||||
| No | 279 (91.5%) | 294 (93.9%) | 345 (93%) | |
| Yes | 26 (8.5%) | 19 (6.1%) | 26 (7%) | 0.49 |
| Chemotherapy | ||||
| No | 304 (99.7%) | 307 (98.1%) | 360 (97%) | |
| Yes | 1 (0.3%) | 6 (1.9%) | 11 (3%) | 0.024 |
| RT treatment | ||||
| No | 159 (52.1%) | 158 (50.5%) | 194 (52.3%) | |
| Yes | 146 (47.9%) | 155 (49.5%) | 177 (47.7%) | 0.88 |
*Chi-square test or Fisher’s exact test